Daesung Microbiological Labs. Statistics
Total Valuation
Daesung Microbiological Labs. has a market cap or net worth of KRW 35.23 billion. The enterprise value is 48.37 billion.
Market Cap | 35.23B |
Enterprise Value | 48.37B |
Important Dates
The next estimated earnings date is Thursday, March 27, 2025.
Earnings Date | Mar 27, 2025 |
Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
Daesung Microbiological Labs. has 3.80 million shares outstanding. The number of shares has increased by 0.25% in one year.
Current Share Class | n/a |
Shares Outstanding | 3.80M |
Shares Change (YoY) | +0.25% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 38.60% |
Owned by Institutions (%) | n/a |
Float | 2.33M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 1.46 |
PB Ratio | 1.03 |
P/TBV Ratio | 1.04 |
P/FCF Ratio | 73.34 |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 123.88, with an EV/FCF ratio of 100.70.
EV / Earnings | -17.28 |
EV / Sales | 2.00 |
EV / EBITDA | 123.88 |
EV / EBIT | n/a |
EV / FCF | 100.70 |
Financial Position
The company has a current ratio of 3.62, with a Debt / Equity ratio of 0.65.
Current Ratio | 3.62 |
Quick Ratio | 1.92 |
Debt / Equity | 0.65 |
Debt / EBITDA | 52.07 |
Debt / FCF | 46.76 |
Interest Coverage | -2.63 |
Financial Efficiency
Return on equity (ROE) is -7.75% and return on invested capital (ROIC) is -2.55%.
Return on Equity (ROE) | -7.75% |
Return on Assets (ROA) | -2.44% |
Return on Capital (ROIC) | -2.55% |
Revenue Per Employee | 180.33M |
Profits Per Employee | -20.89M |
Employee Count | 134 |
Asset Turnover | 0.39 |
Inventory Turnover | 1.74 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.02% in the last 52 weeks. The beta is 0.90, so Daesung Microbiological Labs.'s price volatility has been similar to the market average.
Beta (5Y) | 0.90 |
52-Week Price Change | -20.02% |
50-Day Moving Average | 9,405.00 |
200-Day Moving Average | 10,084.30 |
Relative Strength Index (RSI) | 45.08 |
Average Volume (20 Days) | 21,376 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Daesung Microbiological Labs. had revenue of KRW 24.16 billion and -2.80 billion in losses. Loss per share was -736.04.
Revenue | 24.16B |
Gross Profit | 2.88B |
Operating Income | -2.42B |
Pretax Income | -3.02B |
Net Income | -2.80B |
EBITDA | 431.33M |
EBIT | -2.42B |
Loss Per Share | -736.04 |
Balance Sheet
The company has 9.31 billion in cash and 22.46 billion in debt, giving a net cash position of -13.14 billion or -3,459.07 per share.
Cash & Cash Equivalents | 9.31B |
Total Debt | 22.46B |
Net Cash | -13.14B |
Net Cash Per Share | -3,459.07 |
Equity (Book Value) | 34.31B |
Book Value Per Share | 9,027.97 |
Working Capital | 18.17B |
Cash Flow
In the last 12 months, operating cash flow was 1.56 billion and capital expenditures -1.08 billion, giving a free cash flow of 480.32 million.
Operating Cash Flow | 1.56B |
Capital Expenditures | -1.08B |
Free Cash Flow | 480.32M |
FCF Per Share | 126.40 |
Margins
Gross margin is 11.91%, with operating and profit margins of -10.03% and -11.58%.
Gross Margin | 11.91% |
Operating Margin | -10.03% |
Pretax Margin | -12.51% |
Profit Margin | -11.58% |
EBITDA Margin | 1.79% |
EBIT Margin | -10.03% |
FCF Margin | 1.99% |
Dividends & Yields
Daesung Microbiological Labs. does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.25% |
Shareholder Yield | -0.25% |
Earnings Yield | -7.94% |
FCF Yield | 1.36% |
Stock Splits
The last stock split was on April 25, 2018. It was a forward split with a ratio of 10.
Last Split Date | Apr 25, 2018 |
Split Type | Forward |
Split Ratio | 10 |
Scores
Daesung Microbiological Labs. has an Altman Z-Score of 2.19. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.19 |
Piotroski F-Score | n/a |